The Latisse prescribing information (bimatoprost 0.03%) advises patients who develop a new ocular condition (for example trauma or infection), a sudden decrease in visual acuity, ocular surgery, or any ocular reactions, particularly conjunctivitis and eyelid reactions, to immediately seek their physician's advice. The MedlinePlus glaucoma topic lists sudden eye symptoms for which it says to go to an eye care provider or an emergency room right away. A 2023 review says acquired eyelash loss may be due to a variety of underlying local or systemic disease processes.
What the Latisse label says
The same label lists madarosis and trichorrhexis among reactions identified during postapproval use. The list also includes dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hordeolum, hypersensitivity (local allergic reactions) and lacrimation increased. A 2023 clinical review abstract says madarosis is characterized by either complete or partial loss of eyebrow or eyelash hair.
The label also says these reactions are reported voluntarily from a population of uncertain size, so it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
What MedlinePlus, the NEI and the FDA say about eye warning signs
These are general eye health pages. The claims from them do not mention eyelash products or bimatoprost.
| Question | What the source says |
|---|---|
| What about sudden symptoms? | The MedlinePlus glaucoma topic says sudden symptoms of intense eye pain, blurry vision, red eyes, or an upset stomach (nausea) mean you need to go to your eye care provider or an emergency room right away, and that these could be symptoms of angle-closure glaucoma. |
| Does glaucoma always cause symptoms? | The National Eye Institute (NEI) says that at first glaucoma doesn't usually have any symptoms, and that half of people with glaucoma don't even know they have it. |
| What does the FDA say about eye drops? | An FDA consumer page on eye drops advises stopping eye drops if you experience any issue while using the products, such as discharge from the eye, pain, changes in vision or discomfort. |
Eyelash loss can have more than one cause
A 2023 review says acquired eyebrow and eyelash loss (madarosis) may be due to a variety of underlying local or systemic disease processes, and in other cases it may be idiopathic.
A 2016 review abstract says eyelash hair follicles produce shorter hair shafts, do not possess an arrector pili muscle, have a shorter hair cycle and undergo greying significantly later than scalp hair follicles. It also says knowledge on the biology underlying growth and pigmentation of eyelashes is still rudimentary. The sources used here do not say how many lashes are normally shed.
What a clinician checks
The sources used here do not list the steps a clinician takes to find the cause of eyelash loss or of an eye symptom. Two statements touch on eye pressure. The Latisse label says patients using prostaglandin analogs for intraocular pressure (IOP) reduction should only use Latisse after consulting with their physician and should be monitored for changes to their IOP. The MedlinePlus glaucoma topic states that not everyone with high eye pressure develops glaucoma, and that some people may even get glaucoma with normal eye pressure.
What this does not tell you
This guide does not diagnose and is not a symptom checker. It does not say whether any symptom or any eyelash loss is linked to bimatoprost or to another cause. The label's postapproval list comes from voluntary reports and cannot establish cause. The label statements are about Latisse, not a compounded bimatoprost serum, and the FDA states that compounded drugs are not FDA-approved.
The eye drop advice above is wording from an FDA page about eye drops. This guide does not advise any reader to start, stop or change a product. Which steps are needed for a given person is for a licensed provider.